Hsbc Holdings PLC Intercept Pharmaceuticals, Inc. Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$9.99 - $18.71 $4.56 Million - $8.54 Million	456,623 New	456,623 $8.47 Million
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $1.24 Million - $2.69 Million	-21,678 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$58.69 - $80.46 $1.27 Million - $1.74 Million	21,678 New	21,678 $1.44 Million
Q4 2018 Feb 13, 2019	SELL	$85.79 - $126.46 $507,447 - $748,010	-5,915 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$88.49 - $127.55 $523,418 - $754,458	5,915 New	5,915 $748,000
Q1 2018 May 11, 2018	SELL	$52.72 - $67.25 $21,878 - $27,908	-415 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$58.2 - $72.76 $9,079 - $11,350	156 Added 60.23%	415 $24,000
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $14,765 - $30,756	259	259 $15,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.